pubmed.ncbi.nlm.nih.gov

Silodosin in the treatment of benign prostatic hyperplasia - PubMed

️Fri Jan 01 2010

Review

Silodosin in the treatment of benign prostatic hyperplasia

Maxime Rossi et al. Drug Des Devel Ther. 2010.

Abstract

Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for α(1A)-adrenergic receptors, as compared with both α(1B)- and α(1D) -adrenoceptors, exceeding the selectivity of all currently used α(1)-blockers, and with clinically promising effects.

Keywords: benign prostatic hyperplasia; lower urinary tract symptoms; silodosin; uroselectivity; α1A- blockers.

PubMed Disclaimer

Cited by

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.
Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Ding H, et al. Asian J Androl. 2013 Jan;15(1):121-8. doi: 10.1038/aja.2012.102. Epub 2012 Dec 10. Asian J Androl. 2013. PMID: 23223034 Free PMC article. Review.
Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.
Jindan L, Xiao W, Liping X. Jindan L, et al. Drug Des Devel Ther. 2022 Aug 26;16:2861-2884. doi: 10.2147/DDDT.S373659. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36051157 Free PMC article. Review.
Comparison of silodosin to tamsulosin for medical expulsive treatment of ureteral stones: a systematic review and meta-analysis.
Özsoy M, Liatsikos E, Scheffbuch N, Kallidonis P. Özsoy M, et al. Urolithiasis. 2016 Nov;44(6):491-497. doi: 10.1007/s00240-016-0872-y. Epub 2016 Mar 28. Urolithiasis. 2016. PMID: 27021350 Free PMC article. Review.
Advances in the design and synthesis of prazosin derivatives over the last ten years.
Desiniotis A, Kyprianou N. Desiniotis A, et al. Expert Opin Ther Targets. 2011 Dec;15(12):1405-18. doi: 10.1517/14728222.2011.641534. Epub 2011 Dec 13. Expert Opin Ther Targets. 2011. PMID: 22148952 Free PMC article. Review.

References

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–547. - PubMed
1. Wasserman NF. Benign prostatic hyperplasia: A review and ultrasound classification. Radiol Clin North Am. 2006;44:689–710. - PubMed
1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359–1367. - PubMed
1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol. 2006;49:651–659. - PubMed
1. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol. 2010;28:3–8. - PMC - PubMed

Silodosin in the treatment of benign prostatic hyperplasia - PubMed